<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39334972</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-6382</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Antibiotics (Basel, Switzerland)</Title><ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Increasing Fluroquinolone Susceptibility and Genetic Diversity of ESBL-Producing <i>E. coli</i> from the Lower Respiratory Tract during the COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">797</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics13090797</ELocationID><Abstract><AbstractText>Lower respiratory tract infections (LRTIs) are the fourth leading cause of death worldwide, among which <i>Escherichia coli</i> (<i>E. coli</i>) pneumonia is considered a rare phenomenon. Treatment options for LRTIs have become limited, especially for extended-spectrum β-lactamase-producing <i>E. coli</i> (ESBL-EC), which are usually resistant to other groups of antimicrobials as well. The aim of our study was to compare the phenotypic resistance profiles and genotypes of ESBL-EC isolates associated with LRTIs before (pre-COVID-19) and during (COVID-19) the COVID-19 pandemic. All isolates were screened for antimicrobial resistance genes (ARGs) and virulence-associated genes (VAGs) and assigned to phylogenetic groups, sequence types and clonal groups by PCR. During the pandemic, a significantly lower proportion of ciprofloxacin-, levofloxacin- and trimethoprim-sulfamethoxazole-resistant ESBL-EC isolates was retrieved from lower respiratory tract (LRT) samples. PCR-based genotypization revealed greater clonal diversity and a significantly lower proportion of isolates with <i>bla</i><sub>TEM</sub>, <i>aac(6')-Ib-cr</i> and <i>qacEΔ1</i> genes. In addition, a higher proportion of isolates with the integrase gene <i>int1</i> and virulence genes <i>sat</i> and <i>tsh</i> was confirmed. The lower prevalence of fluoroquinolone resistance and greater genetic diversity of ESBL-EC isolated during the COVID-19 period may have been due to the introduction of new bacterial strains into the hospital environment, along with changes in clinical establishment guidelines and practices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hrovat</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biology, Biotechnical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seme</LastName><ForeName>Katja</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4126-7644</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambrožič Avguštin</LastName><ForeName>Jerneja</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biology, Biotechnical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P1-0198</GrantID><Agency>Slovenian Research and Innovation Agency</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibiotics (Basel)</MedlineTA><NlmUniqueID>101637404</NlmUniqueID><ISSNLinking>2079-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Escherichia coli</Keyword><Keyword MajorTopicYN="N">antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">extended-spectrum β-lactamases</Keyword><Keyword MajorTopicYN="N">lower respiratory tract</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334972</ArticleId><ArticleId IdType="pmc">PMC11428890</ArticleId><ArticleId IdType="doi">10.3390/antibiotics13090797</ArticleId><ArticleId IdType="pii">antibiotics13090797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed.  [(accessed on 5 April 2024)].  Available online:  https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.</Citation></Reference><Reference><Citation>Murray C.J.L., Ikuta K.S., Sharara F., Swetschinski L., Robles Aguilar G., Gray A., Han C., Bisignano C., Rao P., Wool E., et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet. 2022;399:629–655. doi: 10.1016/S0140-6736(21)02724-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>Massella E., Giacometti F., Bonilauri P., Reid C.J., Djordjevic S.P., Merialdi G., Bacci C., Fiorentini L., Massi P., Bardasi L., et al. Antimicrobial Resistance Profile and ExPEC Virulence Potential in Commensal Escherichia coli of Multiple Sources. Antibiotics. 2021;10:351. doi: 10.3390/antibiotics10040351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10040351</ArticleId><ArticleId IdType="pmc">PMC8067153</ArticleId><ArticleId IdType="pubmed">33810387</ArticleId></ArticleIdList></Reference><Reference><Citation>Noster J., Thelen P., Hamprecht A. Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases. Antibiotics. 2021;10:1140. doi: 10.3390/antibiotics10091140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10091140</ArticleId><ArticleId IdType="pmc">PMC8465816</ArticleId><ArticleId IdType="pubmed">34572722</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio D., Ananda-Rajah M.R. Fluoroquinolone antibiotics and adverse events. Aust. Prescr. 2021;44:161–164. doi: 10.18773/austprescr.2021.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.18773/austprescr.2021.035</ArticleId><ArticleId IdType="pmc">PMC8542490</ArticleId><ArticleId IdType="pubmed">34728881</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip. Perspect. Infect. Dis. 2012;2012:976273. doi: 10.1155/2012/976273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/976273</ArticleId><ArticleId IdType="pmc">PMC3477668</ArticleId><ArticleId IdType="pubmed">23097666</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampela I., Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Arch. Med. Res. 2020;51:741–742. doi: 10.1016/j.arcmed.2020.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7275144</ArticleId><ArticleId IdType="pubmed">32546446</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniec K., Beberok A., Pęcak P., Boryczka S., Wrześniok D. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: Preliminary in silico analysis. Pharmacol. Rep. PR. 2020;72:1553–1561. doi: 10.1007/s43440-020-00169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-020-00169-0</ArticleId><ArticleId IdType="pmc">PMC7561236</ArticleId><ArticleId IdType="pubmed">33063271</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri R., Vannini P., Corzani A., Bianco M.T., Franchi F., Cusi M.G., Scolletta S., Arena F., Basagni C., Gusinu R., et al. Rapid Decrease in Fluoroquinolones Consumption following Implementation of a Simple Antimicrobial Stewardship Bundled Intervention in a University Hospital during the COVID-19 Pandemic. Antibiotics. 2023;12:694. doi: 10.3390/antibiotics12040694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12040694</ArticleId><ArticleId IdType="pmc">PMC10135293</ArticleId><ArticleId IdType="pubmed">37107056</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Global Action Plan on Antimicrobial Resistance.  [(accessed on 10 June 2024)].  Available online:  https://www.who.int/publications/i/item/9789241509763.</Citation></Reference><Reference><Citation>Kocsis B., Gulyás D., Szabó D. Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones of Escherichia coli. Life. 2022;12:2077. doi: 10.3390/life12122077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12122077</ArticleId><ArticleId IdType="pmc">PMC9780897</ArticleId><ArticleId IdType="pubmed">36556442</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters P.A., O’Bryan T.A., Zurlo J., Miller D.Q., Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 2003;163:402–410. doi: 10.1001/archinte.163.4.402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.4.402</ArticleId><ArticleId IdType="pubmed">12588198</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushige M., Ngo N.H., Lukmanto D., Fukuda S., Ohneda O. Effect of the COVID-19 pandemic on antibiotic consumption: A systematic review comparing 2019 and 2020 data. Front. Public Health. 2022;10:946077. doi: 10.3389/fpubh.2022.946077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.946077</ArticleId><ArticleId IdType="pmc">PMC9623150</ArticleId><ArticleId IdType="pubmed">36330124</ArticleId></ArticleIdList></Reference><Reference><Citation>Romaszko-Wojtowicz A., Tokarczyk-Malesa K., Doboszyńska A., Glińska-Lewczuk K. Impact of COVID-19 on antibiotic usage in primary care: A retrospective analysis. Sci. Rep. 2024;14:4798. doi: 10.1038/s41598-024-55540-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55540-5</ArticleId><ArticleId IdType="pmc">PMC10899221</ArticleId><ArticleId IdType="pubmed">38413799</ArticleId></ArticleIdList></Reference><Reference><Citation>Siewierska M., Gajda M., Opalska A., Brudło M., Krzyściak P., Gryglewska B., Różańska A., Wójkowska-Mach J. Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study. Pharmacol. Rep. PR. 2023;75:715–725. doi: 10.1007/s43440-023-00479-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-023-00479-z</ArticleId><ArticleId IdType="pmc">PMC10073786</ArticleId><ArticleId IdType="pubmed">37017868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrovat K., Molan K., Seme K., Ambrožič Avguštin J. Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region. Ann. Clin. Microbiol. Antimicrob. 2024;23:6. doi: 10.1186/s12941-023-00664-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-023-00664-1</ArticleId><ArticleId IdType="pmc">PMC10790261</ArticleId><ArticleId IdType="pubmed">38218869</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022.  [(accessed on 16 August 2024)]; Available online:  https://www.cdc.gov/drugresistance/covid19.html.</Citation></Reference><Reference><Citation>Petrakis V., Panopoulou M., Rafailidis P., Lemonakis N., Lazaridis G., Terzi I., Papazoglou D., Panagopoulos P. The Impact of the COVID-19 Pandemic on Antimicrobial Resistance and Management of Bloodstream Infections. Pathogens. 2023;12:780. doi: 10.3390/pathogens12060780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12060780</ArticleId><ArticleId IdType="pmc">PMC10302285</ArticleId><ArticleId IdType="pubmed">37375470</ArticleId></ArticleIdList></Reference><Reference><Citation>Khouja T., Mitsantisuk K., Tadrous M., Suda K.J. Global consumption of antimicrobials: Impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19) J. Antimicrob. Chemother. 2022;77:1491–1499. doi: 10.1093/jac/dkac028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac028</ArticleId><ArticleId IdType="pubmed">35178565</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight G.M., Glover R.E., McQuaid C.F., Olaru I.D., Gallandat K., Leclerc Q.J., Fuller N.M., Willcocks S.J., Hasan R., van Kleef E., et al. Antimicrobial resistance and COVID-19: Intersections and implications. eLife. 2021;10:e64139. doi: 10.7554/eLife.64139.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.64139</ArticleId><ArticleId IdType="pmc">PMC7886324</ArticleId><ArticleId IdType="pubmed">33588991</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusic D., Vilovic M., Bukic J., Leskur D., Seselja Perisin A., Kumric M., Martinovic D., Petric A., Modun D., Bozic J. Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks. Life. 2021;11:220. doi: 10.3390/life11030220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11030220</ArticleId><ArticleId IdType="pmc">PMC8000815</ArticleId><ArticleId IdType="pubmed">33801799</ArticleId></ArticleIdList></Reference><Reference><Citation>ECDC  Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report for 2022.  [(accessed on 12 June 2024)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2022.</Citation></Reference><Reference><Citation>ECDC  Antimicrobial Consumption in the EU/EEA (ESAC-Net)—Annual Epidemiological Report for 2022.  [(accessed on 12 June 2024)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2022.</Citation></Reference><Reference><Citation>EMA  Quinolone- and Fluoroquinolone-Containing Medicinal Products-Referral.  [(accessed on 12 June 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products.</Citation></Reference><Reference><Citation>Abdelaziz Abdelmoneim S., Mohamed Ghazy R., Anwar Sultan E., Hassaan M.A., Anwar Mahgoub M. Antimicrobial resistance burden pre and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: A comparative cross-sectional study. Sci. Rep. 2024;14:7176. doi: 10.1038/s41598-024-56254-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-56254-4</ArticleId><ArticleId IdType="pmc">PMC10966009</ArticleId><ArticleId IdType="pubmed">38531847</ArticleId></ArticleIdList></Reference><Reference><Citation>Araújo M.R.B., Sant’Anna L.O., Santos N., Seabra L.F., Santos L.S.D. Monitoring fluoroquinolone resistance among ESBL-positive and ESBL-negative Escherichia coli strains isolated from urinary tract infections: An alert for empirical treatment. Rev. Soc. Bras. Med. Trop. 2023;56:e0513. doi: 10.1590/0037-8682-0513-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0513-2022</ArticleId><ArticleId IdType="pmc">PMC10109344</ArticleId><ArticleId IdType="pubmed">37075453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettani Halabi M., Lahlou F.A., Diawara I., El Adouzi Y., Marnaoui R., Benmessaoud R., Smyej I. Antibiotic Resistance Pattern of Extended Spectrum Beta Lactamase Producing Escherichia coli Isolated From Patients with Urinary Tract Infection in Morocco. Front. Cell Infect. Microbiol. 2021;11:720701. doi: 10.3389/fcimb.2021.720701.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.720701</ArticleId><ArticleId IdType="pmc">PMC8418096</ArticleId><ArticleId IdType="pubmed">34490146</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitout J.D., DeVinney R. Escherichia coli ST131: A multidrug-resistant clone primed for global domination. F1000Research. 2017;6 doi: 10.12688/f1000research.10609.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.10609.1</ArticleId><ArticleId IdType="pmc">PMC5333602</ArticleId><ArticleId IdType="pubmed">28344773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitout J.D.D., Peirano G., Chen L., DeVinney R., Matsumura Y. Escherichia coli ST1193: Following in the Footsteps of E. coli ST131. Antimicrob. Agents Chemother. 2022;66:e0051122. doi: 10.1128/aac.00511-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00511-22</ArticleId><ArticleId IdType="pmc">PMC9295538</ArticleId><ArticleId IdType="pubmed">35658504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassetti S., Ciani L., Luzzi V., Gori L., Trigiani M., Giuntoli L., Lavorini F., Poletti V., Ravaglia C., Torrego A., et al. Utility of bronchoalveolar lavage for COVID-19: A perspective from the Dragon consortium. Front. Med. 2024;11:1259570. doi: 10.3389/fmed.2024.1259570.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1259570</ArticleId><ArticleId IdType="pmc">PMC10869531</ArticleId><ArticleId IdType="pubmed">38371516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ružić Gorenjec N., Kejžar N., Manevski D., Pohar Perme M., Vratanar B., Blagus R. COVID-19 in Slovenia, from a Success Story to Disaster: What Lessons Can Be Learned? Life. 2021;11:1045. doi: 10.3390/life11101045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11101045</ArticleId><ArticleId IdType="pmc">PMC8541564</ArticleId><ArticleId IdType="pubmed">34685416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagar T., Tomsic S., Zadnik V., Bric N., Birk M., Vurzer B., Mihor A., Lokar K., Oblak I. Impact of the COVID-19 epidemic on cancer burden and cancer care in Slovenia: A follow-up study. Radiol. Oncol. 2022;56:488–500. doi: 10.2478/raon-2022-0050.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/raon-2022-0050</ArticleId><ArticleId IdType="pmc">PMC9784361</ArticleId><ArticleId IdType="pubmed">36503711</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—27 July 2020.  [(accessed on 10 June 2024)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---27-july-2020.</Citation></Reference><Reference><Citation>Hrovat K., Zupančič J., Seme K., Avguštin J.A. QAC Resistance Genes in ESBL-Producing E. coli Isolated from Patients with Lower Respiratory Tract Infections in the Central Slovenia Region-A 21-Year Survey. Trop. Med. Infect. Dis. 2023;8:273. doi: 10.3390/tropicalmed8050273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed8050273</ArticleId><ArticleId IdType="pmc">PMC10221947</ArticleId><ArticleId IdType="pubmed">37235321</ArticleId></ArticleIdList></Reference><Reference><Citation>EUCAST  Breakpoint Tables for Interpretation of MICs and Zone Diameters. Versions 4.0 to 9.0.  [(accessed on 5 April 2024)].  Available online:  https://www.eucast.org/clinical_breakpoints/</Citation></Reference><Reference><Citation>EUCAST  Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. Version 2.0.  [(accessed on 5 April 2024)]. pp. 1–43. Available online:  http://www.eucast.org/resistance_mechanisms/</Citation></Reference><Reference><Citation>Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2011.03570.x</ArticleId><ArticleId IdType="pubmed">21793988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfensberger A., Kuster S.P., Marchesi M., Zbinden R., Hombach M. The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods. Antimicrob. Resist. Infect. Control. 2019;8:193. doi: 10.1186/s13756-019-0614-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-019-0614-3</ArticleId><ArticleId IdType="pmc">PMC6883537</ArticleId><ArticleId IdType="pubmed">31798839</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bouguenec C., Archambaud M., Labigne A. Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J. Clin. Microbiol. 1992;30:1189–1193. doi: 10.1128/jcm.30.5.1189-1193.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.30.5.1189-1193.1992</ArticleId><ArticleId IdType="pmc">PMC265248</ArticleId><ArticleId IdType="pubmed">1349900</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodford N., Fagan E.J., Ellington M.J. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J. Antimicrob. Chemother. 2006;57:154–155. doi: 10.1093/jac/dki412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki412</ArticleId><ArticleId IdType="pubmed">16284100</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallenne C., Da Costa A., Decré D., Favier C., Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 2010;65:490–495. doi: 10.1093/jac/dkp498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkp498</ArticleId><ArticleId IdType="pubmed">20071363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattoir V., Poirel L., Rotimi V., Soussy C.J., Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother. 2007;60:394–397. doi: 10.1093/jac/dkm204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkm204</ArticleId><ArticleId IdType="pubmed">17561500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattoir V., Weill F.X., Poirel L., Fabre L., Soussy C.J., Nordmann P. Prevalence of qnr genes in Salmonella in France. J. Antimicrob. Chemother. 2007;59:751–754. doi: 10.1093/jac/dkl547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkl547</ArticleId><ArticleId IdType="pubmed">17307773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraychete G.B., Botelho L.A., Campana E.H., Picão R.C., Bonelli R.R. Updated Multiplex PCR for Detection of All Six Plasmid-Mediated qnr Gene Families. Antimicrob. Agents Chemother. 2016;60:7524–7526. doi: 10.1128/AAC.01447-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01447-16</ArticleId><ArticleId IdType="pmc">PMC5119042</ArticleId><ArticleId IdType="pubmed">27736767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wareham D.W., Umoren I., Khanna P., Gordon N.C. Allele-specific polymerase chain reaction (PCR) for rapid detection of the aac(6′)-Ib-cr quinolone resistance gene. Int. J. Antimicrob. Agents. 2010;36:476–477. doi: 10.1016/j.ijantimicag.2010.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2010.07.012</ArticleId><ArticleId IdType="pubmed">20843664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattoir V., Poirel L., Nordmann P. Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. Antimicrob. Agents Chemother. 2008;52:3801–3804. doi: 10.1128/AAC.00638-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00638-08</ArticleId><ArticleId IdType="pmc">PMC2565908</ArticleId><ArticleId IdType="pubmed">18644958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L., Meng J., McDermott P.F., Wang F., Yang Q., Cao G., Hoffmann M., Zhao S. Presence of disinfectant resistance genes in Escherichia coli isolated from retail meats in the USA. J. Antimicrob. Chemother. 2014;69:2644–2649. doi: 10.1093/jac/dku197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku197</ArticleId><ArticleId IdType="pubmed">24908046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L.H., Sørensen S.J., Jørgensen H.S., Jensen L.B. The prevalence of the OqxAB multidrug efflux pump amongst olaquindox-resistant Escherichia coli in pigs. Microb. Drug Resist. 2005;11:378–382. doi: 10.1089/mdr.2005.11.378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mdr.2005.11.378</ArticleId><ArticleId IdType="pubmed">16359198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Q., Tian Y., Zhang L., Jiang C., Dong D., Li Z., Mao E., Peng Y. Prevalence and quinolone resistance of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in 6 communities and 2 physical examination center populations in Shanghai, China. Diagn. Microbiol. Infect. Dis. 2016;86:428–433. doi: 10.1016/j.diagmicrobio.2016.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2016.07.010</ArticleId><ArticleId IdType="pubmed">27681363</ArticleId></ArticleIdList></Reference><Reference><Citation>Versalovic J., Koeuth T., Lupski J.R. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 1991;19:6823–6831. doi: 10.1093/nar/19.24.6823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/19.24.6823</ArticleId><ArticleId IdType="pmc">PMC329316</ArticleId><ArticleId IdType="pubmed">1762913</ArticleId></ArticleIdList></Reference><Reference><Citation>Clermont O., Christenson J.K., Denamur E., Gordon D.M. The Clermont Escherichia coli phylo-typing method revisited: Improvement of specificity and detection of new phylo-groups. Environ. Microbiol. Rep. 2013;5:58–65. doi: 10.1111/1758-2229.12019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1758-2229.12019</ArticleId><ArticleId IdType="pubmed">23757131</ArticleId></ArticleIdList></Reference><Reference><Citation>Clermont O., Bonacorsi S., Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 2000;66:4555–4558. doi: 10.1128/AEM.66.10.4555-4558.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.66.10.4555-4558.2000</ArticleId><ArticleId IdType="pmc">PMC92342</ArticleId><ArticleId IdType="pubmed">11010916</ArticleId></ArticleIdList></Reference><Reference><Citation>Doumith M., Day M., Ciesielczuk H., Hope R., Underwood A., Reynolds R., Wain J., Livermore D.M., Woodford N. Rapid identification of major Escherichia coli sequence types causing urinary tract and bloodstream infections. J. Clin. Microbiol. 2015;53:160–166. doi: 10.1128/JCM.02562-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02562-14</ArticleId><ArticleId IdType="pmc">PMC4290915</ArticleId><ArticleId IdType="pubmed">25355761</ArticleId></ArticleIdList></Reference><Reference><Citation>Clermont O., Dhanji H., Upton M., Gibreel T., Fox A., Boyd D., Mulvey M.R., Nordmann P., Ruppé E., Sarthou J.L., et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 2009;64:274–277. doi: 10.1093/jac/dkp194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkp194</ArticleId><ArticleId IdType="pubmed">19474064</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.R., Stell A.L. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 2000;181:261–272. doi: 10.1086/315217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315217</ArticleId><ArticleId IdType="pubmed">10608775</ArticleId></ArticleIdList></Reference><Reference><Citation>Starčič Erjavec M., Palandačić A., Žgur-Bertok D., Ambrožič Avguštin J. Genetic background of uropathogenic Escherichia coli isolates from Slovenia in relation to fluoroquinolone and sulfamethoxazole/trimethoprim resistance. Acta Biol. Slov. 2011;54:5–13. doi: 10.14720/abs.54.2.15475.</Citation><ArticleIdList><ArticleId IdType="doi">10.14720/abs.54.2.15475</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.R., Russo T.A., Tarr P.I., Carlino U., Bilge S.S., Vary J.C., Jr., Stell A.L. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN (E. coli), among Escherichia coli isolates from patients with urosepsis. Infect. Immun. 2000;68:304–307. doi: 10.1128/IAI.68.5.3040-3047.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.68.5.3040-3047.2000</ArticleId><ArticleId IdType="pmc">PMC97527</ArticleId><ArticleId IdType="pubmed">10769012</ArticleId></ArticleIdList></Reference><Reference><Citation>Janben T., Schwarz C., Preikschat P., Voss M., Philipp H.C., Wieler L.H. Virulence-associated genes in avian pathogenic Escherichia coli (APEC) isolated from internal organs of poultry having died from colibacillosis. Int. J. Med. Microbiol. 2001;291:371–378. doi: 10.1078/1438-4221-00143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1078/1438-4221-00143</ArticleId><ArticleId IdType="pubmed">11727821</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.R., Brown J.J. A novel multiply primed polymerase chain reaction assay for identification of variant papG genes encoding the Gal(alpha 1-4)Gal-binding PapG adhesins of Escherichia coli. J. Infect. Dis. 1996;173:920–926. doi: 10.1093/infdis/173.4.920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/173.4.920</ArticleId><ArticleId IdType="pubmed">8603972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J., Navia M.M., Vila J., Gascón J. Prevalence of the sat gene among clinical isolates of Shigella spp. causing travelers’ diarrhea: Geographical and specific differences. J. Clin. Microbiol. 2002;40:1565–1566. doi: 10.1128/JCM.40.4.1565-1566.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.40.4.1565-1566.2002</ArticleId><ArticleId IdType="pmc">PMC140325</ArticleId><ArticleId IdType="pubmed">11923399</ArticleId></ArticleIdList></Reference><Reference><Citation>Parham N.J., Pollard S.J., Desvaux M., Scott-Tucker A., Liu C., Fivian A., Henderson I.R. Distribution of the serine protease autotransporters of the Enterobacteriaceae among extraintestinal clinical isolates of Escherichia coli. J. Clin. Microbiol. 2005;43:4076–4082. doi: 10.1128/JCM.43.8.4076-4082.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.8.4076-4082.2005</ArticleId><ArticleId IdType="pmc">PMC1233896</ArticleId><ArticleId IdType="pubmed">16081954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert S., Rakin A., Karch H., Carniel E., Heesemann J. Prevalence of the “high-pathogenicity island” of Yersinia species among Escherichia coli strains that are pathogenic to humans. Infect. Immun. 1998;66:480–485. doi: 10.1128/IAI.66.2.480-485.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.66.2.480-485.1998</ArticleId><ArticleId IdType="pmc">PMC107931</ArticleId><ArticleId IdType="pubmed">9453599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., Terai A., Yuri K., Kurazono H., Takeda Y., Yoshida O. Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol. Med. Microbiol. 1995;12:85–90. doi: 10.1111/j.1574-695X.1995.tb00179.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.1995.tb00179.x</ArticleId><ArticleId IdType="pubmed">8589667</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.R., Stapleton A.E., Russo T.A., Scheutz F., Brown J.J., Maslow J.N. Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG. Infect. Immun. 1997;65:2153–2159. doi: 10.1128/iai.65.6.2153-2159.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.65.6.2153-2159.1997</ArticleId><ArticleId IdType="pmc">PMC175297</ArticleId><ArticleId IdType="pubmed">9169745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadnov M., Barbič D., Žgur-Bertok D., Erjavec M.S. Escherichia coli isolated from feces of brown bears (Ursus arctos) have a lower prevalence of human extraintestinal pathogenic E. coli virulence-associated genes. Can. J. Vet. Res. = Rev. Can. De Rech. Vet. 2017;81:59–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5220600</ArticleId><ArticleId IdType="pubmed">28154465</ArticleId></ArticleIdList></Reference><Reference><Citation>Trkov M., Dovečar D., Paragi M., Ambrožič Avguštin J. Phylogenetic grouping of Escherichia coli isolates from patients’ stool samples with diarrhoea. Clin. Microbiol. Infect. 2008;14:157</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>